

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited taken responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



泰 達

天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code : 8189)

SUPPLEMENTAL ANNOUNCEMENT ABOUT DISCLOSEABLE TRANSACTION

References are made to the announcement (the “Announcement”) of Tianjin TEDA Biomedical Engineering Company Limited (the “Company”) dated 27 March 2024. Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

The principle business activity of the Purchaser is investment management, and the ultimate beneficial owner of the Purchaser is Mr. Qin Wenhua (“Mr. Qin”), who is a citizen of the People’s Republic of China.

The net assets value of Shanghai Weidi Network Technology Company Limited (“Shanghai Weidi”) for the year ended 31 December 2023 was RMB4,678,393.

The revenue and net loss (both before and after taxation) attributable to Shanghai Weidi for the two financial years immediately preceding the disposal was as follows:

	For the year ended 31 December 2022 RMB (audited)	For the year ended 31 December 2023 RMB (audited)
Revenue	10,736,959	2,159,592
Loss before taxation	(3,114,124)	(6,600,482)
Loss after taxation	(3,114,124)	(6,600,482)

The net loss for the financial years ended 31 December 2022 and 31 December 2023 disclosed in the Company’s announcement dated 27 March 2024 was incorrect, it was for the discontinued operation of “Health care products (wine) and related services”, which included the net loss of Shanghai Weidi and part of net profit/loss of Teda Health Management Services (Dongguan) Co., Ltd (“Teda Dongguan”). Teda Dongguan is a wholly-owned subsidiary of the Company.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
23 May 2024

As at the date of this announcement, the executive directors of the Company are Sun Li and He Xin; the non-executive directors of the Company are Cao Aixin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.